Rhumatologie. Anti-IL-6 : nouvelles perspectives thérapeutiques [Anti-IL-6 : new therapeutic trends]

Details

Serval ID
serval:BIB_3749B8BF0768
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Rhumatologie. Anti-IL-6 : nouvelles perspectives thérapeutiques [Anti-IL-6 : new therapeutic trends]
Journal
Revue medicale suisse
Author(s)
Candil M., Zufferey P.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
11/01/2017
Peer-reviewed
Oui
Volume
13
Number
544-545
Pages
105-109
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The anti-IL-6 tocilizumab is a recognized treatment in rheumatoid arthritis and in systemic juvenile idiopathic arthritis. Almost ten years after its first use, there is more information about its security profile and its indication should be extended to other systemic inflammatory diseases, such as the giant cell arteritis. New molecules targetting the IL-6 pathway are under validation : sarilumab, sirukumab and olokizumab. Here is a brief state of the future outlook and trends of this therapeutic class.

Keywords
Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Arthritis, Rheumatoid/drug therapy, Drugs, Investigational/therapeutic use, Giant Cell Arteritis/drug therapy, Humans, Inflammation/drug therapy, Interleukin-6/antagonists & inhibitors, Interleukin-6/immunology, Rheumatology/methods, Rheumatology/trends
Pubmed
Create date
18/08/2017 14:46
Last modification date
20/08/2019 13:25
Usage data